Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Abeona Therapeutics is a clinical-stage gene and cell therapy company focused on developing AAV-based therapies for rare genetic diseases, including recessive dystrophic epidermolysis bullosa (RDEB) and Batten disease. With zero revenue, a $300M market cap, and negative operating cash flow of $100M annually, the company is a pre-commercial biotech dependent on clinical trial outcomes and capital markets access to fund operations through potential FDA approvals.
Abeona operates as a clinical-stage biotech developing one-time gene therapies for rare genetic diseases with high unmet need. The business model depends on successfully advancing lead candidates through Phase 1/2/3 trials, securing FDA approval, and commercializing therapies at premium pricing (typically $500K-$2M+ per patient for gene therapies). Revenue generation is 3-5+ years away, contingent on clinical success, regulatory approval, and reimbursement negotiations with payers. Current operations are funded through equity raises and potential non-dilutive financing (grants, partnerships). The 9.74x current ratio and minimal debt (0.14x D/E) provide runway, but cash burn of $100M annually creates urgency for clinical milestones or capital events.
Clinical trial data readouts for lead programs (RDEB, Batten disease) - positive efficacy/safety data can drive 50-200%+ moves
FDA regulatory interactions - IND clearances, Fast Track/Orphan Drug designations, Breakthrough Therapy status, or clinical holds
Capital raises and cash runway updates - dilutive equity offerings typically pressure stock 10-30%, while non-dilutive partnerships are positive
Competitive clinical data from rival gene therapy companies targeting same indications
Manufacturing and CMC progress for AAV vector production at commercial scale
Binary clinical trial risk - single failed Phase 2/3 trial can render company value near-zero given concentrated pipeline in rare diseases with small patient populations
Gene therapy manufacturing complexity and scalability - AAV vector production requires specialized facilities with high failure rates and regulatory scrutiny
Reimbursement uncertainty for ultra-high-cost gene therapies ($1M+ per patient) as payers increasingly push back on pricing and demand outcomes-based contracts
Regulatory pathway evolution - FDA standards for gene therapy approval are tightening post-2023 safety concerns in other AAV programs
Multiple well-funded competitors developing gene therapies for overlapping rare disease indications with potentially superior data or faster timelines
Risk of being second-to-market in orphan indications where first approved therapy captures majority of small patient population
Larger pharma companies (Pfizer, Novartis, BioMarin) with deeper resources and established gene therapy platforms entering same therapeutic areas
Cash runway risk - with $100M annual burn and $300M market cap, company likely needs capital raise within 12-18 months, creating dilution overhang
Equity financing risk in adverse market conditions - biotech IPO/follow-on windows close during market volatility, potentially forcing unfavorable terms
Abnormally high ROE (78.4%) and ROA (35.6%) despite losses suggest negative equity or unusual balance sheet structure requiring investigation
low - Pre-revenue biotech with no direct GDP linkage. Clinical trial timelines and FDA processes are largely insulated from economic cycles. However, severe recessions can impact: (1) ability to raise capital as risk appetite declines, (2) hospital/site participation in trials during healthcare system stress, and (3) future reimbursement environment if approved during downturn.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (NPV of potential product revenues 5-10 years out declines significantly). Higher rates also increase cost of capital for future financing rounds and reduce investor appetite for speculative, cash-burning biotechs as safer fixed-income yields become attractive. The 1.6x P/B and 693x P/S multiples compress materially in rising rate environments. Additionally, cash held on balance sheet earns higher returns in rising rate environment (minor positive offset).
minimal - Company has negligible debt (0.14x D/E) and is not dependent on credit markets for operations. Primary financing is equity-based. Credit conditions matter indirectly through biotech sector sentiment and availability of venture/growth capital for follow-on rounds.
growth - Attracts speculative biotech investors seeking asymmetric risk/reward from binary clinical catalysts. Typical holders include specialized healthcare hedge funds, biotech-focused venture investors, and retail traders betting on FDA approval lottery tickets. Not suitable for value or income investors given zero revenue, negative cash flow, and no dividend. The -12.6% 1-year return but +21.9% 3-month return suggests event-driven volatility around clinical updates.
high - Clinical-stage biotechs with $300M market caps routinely experience 30-50% single-day moves on trial data. The 6-month return of -25.1% versus 3-month return of +21.9% demonstrates extreme volatility. Beta likely 1.5-2.0x relative to biotech sector indices. Stock is illiquid with wide bid-ask spreads, amplifying volatility. Options market typically prices 80-120% implied volatility around known data catalysts.
